Skip to content
Screener

Rigel Pharmaceuticals RIGL Total costs & expenses

Total costs & expenses at other companies

Amgen logo
AmgenAMGN
$6.54B+0.3%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$155.3M+11.3%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$21.05M-13.1%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$43.47M+35.9%
Opko Health logo
Opko HealthOPK
$170.55M-21.3%
TG Therapeutics logo
TG TherapeuticsTGTX
$218.66M+106%

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K
Free cash flow-$22.0M

Valuation

See full
Market cap$778.2M+29.7%
Enterprise value$822.1M+50.0%
P/E2.1×-4.0×
P/S2.6×+0.4×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%

Returns & leverage

See full
Return on equity174.1%
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CostsAndExpenses.

The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:05 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001034842-26-000032
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Cost of product sales4,6064,409
Research and development11,6768,436
Selling, general and administrative30,65127,715
Total costs and expenses46,93340,560
Income from operations11,88512,773
Interest income1,205591
Interest expense(1,433)(1,853)
Income before income taxes11,65711,511

Item 1. Financial Statements

FAQ

What is Rigel Pharmaceuticals's total costs & expenses?
Rigel Pharmaceuticals (RIGL) reported total costs & expenses of $46.93M in Q1 2026.
How has Rigel Pharmaceuticals's total costs & expenses changed year-over-year?
Rigel Pharmaceuticals's total costs & expenses increased by 15.7% year-over-year, from $40.56M to $46.93M.
What is the long-term trend for Rigel Pharmaceuticals's total costs & expenses?
Over 4 years (2021 to 2025), Rigel Pharmaceuticals's total costs & expenses has grown at a 1.1% compound annual growth rate (CAGR), from $161.73M to $168.82M.
What does total costs & expenses mean?
This metric represents the aggregate of all operating and non-operating costs incurred by the company to support its business activities, including research and development, selling, general, and administrative expenses, and cost of product sales. It serves as a comprehensive measure of the total resource consumption required to sustain operations and bring pharmaceutical products to market. Monitoring this figure allows investors to evaluate the company's overall cost structure and operational efficiency relative to its revenue generation.

Ask your AI about Rigel Pharmaceuticals's total costs & expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude